Inflammatory Bowel Disease Center at NYU Langone Health, Division of Gastroenterology, Department of Medicine, NYU School of Medicine, New York, New York, USA.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Am J Gastroenterol. 2024 Feb 1;119(2):313-322. doi: 10.14309/ajg.0000000000002502. Epub 2023 Oct 9.
Data suggest atherosclerotic-related inflammation may play a role in the pathogenesis of inflammatory bowel disease (IBD), but large-scale studies are missing.
In this nationwide case-control study, we used the Swedish Patient Register and the Epidemiology Strengthened by histoPathology Reports in Sweden cohort to identify adult cases of incident IBD between 2002 and 2021, with each case matched to up to 10 general population controls. We used conditional logistic regression to calculate odds ratios (OR) for exposure to an atherosclerotic-related condition (myocardial infarction, thromboembolic stroke, or atherosclerosis itself) before being diagnosed with IBD.
There were a total of 56,212 individuals with IBD and 531,014 controls. Of them, 2,334 (4.2%) cases and 18,222 (3.4%) controls had a prior diagnosis of an atherosclerotic-related condition, corresponding to an OR of 1.30 (95% confidence interval [CI] 1.24-1.37). Results were statistically significant for both Crohn's disease (OR 1.37, 95% CI 1.26-1.48) and ulcerative colitis (OR 1.27, 95% CI 1.20-1.35) and for individuals who developed IBD at 40-59 years of age and 60 years or older. In addition, associations persisted when adjusting for underlying comorbidities, including the presence of immune-mediated diseases and prior aspirin and/or statin use. The highest odds of an atherosclerotic-related condition were seen in the 6-12 months before IBD diagnosis, though odds were increased even ≥5 years before. A higher magnitude of odds was also observed when having 2 or more atherosclerotic-related conditions when compared with having only 1 condition.
A history of an atherosclerotic-related condition is associated with increased odds of developing IBD, particularly among older adults. Future studies should investigate whether drugs targeting atherosclerotic-related inflammation may prevent IBD in higher-risk individuals.
有数据表明,动脉粥样硬化相关炎症可能在炎症性肠病(IBD)的发病机制中起作用,但缺乏大规模的研究。
在这项全国性的病例对照研究中,我们使用瑞典患者登记处和瑞典强化流行病学与组织病理学报告队列,来确定 2002 年至 2021 年间新发 IBD 的成年病例,每个病例与最多 10 名普通人群对照相匹配。我们使用条件逻辑回归来计算在诊断为 IBD 之前暴露于动脉粥样硬化相关疾病(心肌梗死、血栓栓塞性中风或动脉粥样硬化本身)的比值比(OR)。
共有 56212 名 IBD 患者和 531014 名对照者。其中,2334 例(4.2%)病例和 18222 例(3.4%)对照者在之前被诊断出患有动脉粥样硬化相关疾病,相应的 OR 为 1.30(95%置信区间 [CI] 1.24-1.37)。结果对于克罗恩病(OR 1.37,95% CI 1.26-1.48)和溃疡性结肠炎(OR 1.27,95% CI 1.20-1.35)均具有统计学意义,且对于在 40-59 岁和 60 岁或以上诊断出 IBD 的个体也具有统计学意义。此外,在调整了潜在合并症(包括免疫介导性疾病以及既往使用阿司匹林和/或他汀类药物)后,关联仍然存在。在 IBD 诊断前 6-12 个月内,动脉粥样硬化相关疾病的发生几率最高,但在诊断前≥5 年,这种几率也会增加。与仅有一种动脉粥样硬化相关疾病相比,同时存在 2 种或更多动脉粥样硬化相关疾病时,发生几率也更高。
动脉粥样硬化相关疾病史与 IBD 的发生几率增加相关,尤其是在老年人中。未来的研究应该探讨针对动脉粥样硬化相关炎症的药物是否可以预防高危人群中的 IBD。